WEEK MILLIONGIAND	(Affix identifica	ition label here)						
<b>Queensland</b> Government	URN:							
	Family name:							
* PAEDIATRIC	Given name(s):							
Sepsis Pathway	Address:							
Facility:	Date of birth:	Sex: M F I						
Clinical pathways never replace clinical judgement. Use this pathway in children younger than 16 years.								
16–18 year olds may use the adult or paediatric sepsis		an to years.						
Sepsis is infection with organ dysfunction. Se	psis is a MEDICAL EMERGENO	Y.						
SCREEN AND RECOGNISE								
Screening initiated: DD / MM / YY HH : MM (24)	hr)							
Could it be sepsis?	<b>*</b> * *							
$\square$ Signs of infection or history and evidence of fever or	hypothermia							
PLUS ANY of the following								
	d behaviour or reduced level of cons ounger than 3 months	ciousness						
	s admission within the last 30 days							
	jinal or Torres Strait Islander person							
*For Oncology patients refer to 'Management of Suspec	cted Neutropenic Sepsis Pathway (S	(W796)						
	YES							
Document full set of observations in CEWT including	ng blood pressure and AVPU							
	THEN							
Does the patient have ANY features of severe illness								
Severe respiratory distress, tachypnoea or apnoea (0		red AVPU						
☐ Severe tachycardia (CEWT heart rate score 3)		r skin perfusion or cold extremities						
☐ Hypotension (CEWT blood pressure score ≥2)	□Lac	tate ≥2mmol/L (if known)						
Other laboratory features of severe illness (if known								
☐ Low platelets ☐ Elevated creatinine ☐ Elevated	ted INR or bilirubin	CRP						
These laboratory tests are not mandatory								
YES		<b>♦</b> NO						
	Do you still su	spect sepsis?						
	YES	<b>↓</b> NO						
	Patient MAY have sepsis	Patient UNLIKELY to						
	Targeted history and examination	have sepsis now						
Immediate senior medical review or call Retrieval Services Queensland (RSQ)	Obtain senior medical review or	Reassess and escalate     as indicated						
1300 799 127	consider calling RSQ	as illuicateu						
Immediate monitoring in close observation area								
THEN	<b>↓</b> THEN	<b>↓</b> THEN						
		Give Paediatric Sepsis Checklist to parent or						
Senior medical review attended: H. : MM (24hr)								
		carer (tear off back page)						
Does the senior clinician think sepsis is likely?	shock <i>OR</i> Unlikely sensis	carer (tear off back page)						
	shock <i>OR</i> Unlikely sepsis							



Escalate to MET, PICU, ICU or RSQ 1300 799 127

Signatur	e Log Every person documenting in this of	Every person documenting in this clinical pathway must supply a sample of their initials and signature below					
Initials	Signature	Print name	Role				





(Affix identification labe	el here)
URN:	
Family name:	
Given name(s):	
Address:	
Date of birth:	Sex: M F I

Sepsis Pathway		
Ocpoio i attiway		
	Date of birth: Sex:	M □ F □ I
ACUTE RESUSCITATION TREATMENT BUNDL	E	
Complete actions 1–6 within:		
1 hour of recognition of shock or where there is high lik	celihood of sepsis	
3 hours to administer antimicrobials where there is less		oritise timely collection of
all relevant microbiological samples according to suspe		
1. Notify the Senior Medical Officer or RSQ for review	ew	Consultant notified
Refer to Consultant Paediatrician		
Notify Nursing Team Leader or Senior Nurse on cal		
2. Monitor oxygen saturations and maintain 94% or	greater	Oxygen saturations maintained
3. IV or intraosseous access and blood culture		Blood cultures
Obtain intraosseous access after two failed attempt	ts at IV cannulation	obtained
Take blood culture (2–6mL) prior to antibiotics		☐ Lactate taken
<ul> <li>Take lactate, VBG and blood glucose level</li> </ul>		
Take FBC, CRP, Chem20, coagulation studies and	when possible, all appropriate cultures	
4. Commence appropriate IV or intraosseous antibi	otics	Antibiotic
<ul> <li>Check allergies and presence of MRSA risk factors</li> </ul>		commenced
<ul> <li>Prescribe antibiotics according to the guidelines in</li> </ul>		
Give intramuscular antibiotics if failed IV or intraoss	seous access	
Suspected source of infection:		
Sepsis where meningitis possible <i>OR</i> bacterial me		
Sepsis (source unknown, but bacterial meningitis		
☐ Febrile neutropenia (refer to 'Management of Susy Neutropenic Sepsis Pathway [SW796]')	pected Cellulitis, skeletal or soft tissue Central venous access device	<b>:</b>
☐ Toxic Shock Syndrome	☐ Pneumonia	
5. Commence fluid resuscitation		Fluid bolus
Administer rapid isotonic fluid bolus IV or intraossed	ous 10–20ml /kg: assess response	commenced
Consider repeating up to 40–60mL/kg isotonic fluid		
Observe for signs of fluid overload (hepatomegaly)		
<ul> <li>If hypoglycaemic, then give 2mL/kg glucose 10%</li> </ul>		
Consider second IV or intraosseous access		
6. Consider inotropic support and prepare early		☐ Inotrope
		-
Consider IV or intraosseous adrenaline infusion if n	no or limited improvement in haemodynamic	considered
status after 40–60mL/kg of fluid		-
status after 40–60mL/kg of fluid • Prepare adrenaline (epinephrine) infusion by dilutin	ng 1mg (1mL of 1:1000) to 50mL with sodium	-
status after 40–60mL/kg of fluid • Prepare adrenaline (epinephrine) infusion by dilutin chloride 0.9% or glucose 5%; commence infusion a	ng 1mg (1mL of 1:1000) to 50mL with sodium at 0.1–0.5 microgram/kg/min (see CREDD	-
status after 40–60mL/kg of fluid • Prepare adrenaline (epinephrine) infusion by dilutin	ng 1mg (1mL of 1:1000) to 50mL with sodium at 0.1–0.5 microgram/kg/min (see CREDD	-
status after 40–60mL/kg of fluid • Prepare adrenaline (epinephrine) infusion by dilutin chloride 0.9% or glucose 5%; commence infusion a infusion chart for equivalent mL/hr for child's weight • Call PICU, ICU or RSQ 1300 799 127	ng 1mg (1mL of 1:1000) to 50mL with sodium at 0.1–0.5 microgram/kg/min (see CREDD	-
status after 40–60mL/kg of fluid  • Prepare adrenaline (epinephrine) infusion by dilutin chloride 0.9% or glucose 5%; commence infusion a infusion chart for equivalent mL/hr for child's weight  • Call PICU, ICU or RSQ 1300 799 127  BEREAVEMENT	ng 1mg (1mL of 1:1000) to 50mL with sodium at 0.1–0.5 microgram/kg/min (see CREDD t)	considered
status after 40–60mL/kg of fluid  • Prepare adrenaline (epinephrine) infusion by dilutin chloride 0.9% or glucose 5%; commence infusion a infusion chart for equivalent mL/hr for child's weight  • Call PICU, ICU or RSQ 1300 799 127  BEREAVEMENT  Refer to CHQ Bereavement Service (1800 080 316) of	ng 1mg (1mL of 1:1000) to 50mL with sodium at 0.1–0.5 microgram/kg/min (see CREDD t)  or email CHQ_Bereavement@health.qld.gov.a	considered
status after 40–60mL/kg of fluid  • Prepare adrenaline (epinephrine) infusion by dilutin chloride 0.9% or glucose 5%; commence infusion a infusion chart for equivalent mL/hr for child's weight  • Call PICU, ICU or RSQ 1300 799 127  BEREAVEMENT  Refer to CHQ Bereavement Service (1800 080 316) or offer for family to spend time with child after death	og 1mg (1mL of 1:1000) to 50mL with sodium at 0.1–0.5 microgram/kg/min (see CREDD t)  or email CHQ_Bereavement@health.qld.gov.a	considered  au  busis related death
status after 40–60mL/kg of fluid  • Prepare adrenaline (epinephrine) infusion by dilutin chloride 0.9% or glucose 5%; commence infusion a infusion chart for equivalent mL/hr for child's weight  • Call PICU, ICU or RSQ 1300 799 127  BEREAVEMENT  Refer to CHQ Bereavement Service (1800 080 316) or General Control of the control of the control of the certificate certificate control of the certificate ce	og 1mg (1mL of 1:1000) to 50mL with sodium at 0.1–0.5 microgram/kg/min (see CREDD t)  or email CHQ_Bereavement@health.qld.gov.a	considered  au  busis related death
status after 40–60mL/kg of fluid  • Prepare adrenaline (epinephrine) infusion by dilutin chloride 0.9% or glucose 5%; commence infusion a infusion chart for equivalent mL/hr for child's weight  • Call PICU, ICU or RSQ 1300 799 127  BEREAVEMENT  Refer to CHQ Bereavement Service (1800 080 316) or Grammer of G	or email CHQ_Bereavement@health.qld.gov.a  Inform Sepsis Care Coordinator of sepsis Care Goldward Colors and Charange follow-up meeting to discuss	considered  u  psis related death events of hospitalisation
status after 40–60mL/kg of fluid  • Prepare adrenaline (epinephrine) infusion by dilutin chloride 0.9% or glucose 5%; commence infusion a infusion chart for equivalent mL/hr for child's weight  • Call PICU, ICU or RSQ 1300 799 127  BEREAVEMENT  Refer to CHQ Bereavement Service (1800 080 316) or Grandle of Grandle of the Grandle of Grandle of Charles of Service (1800 080 316) or Grandle of Grandle of Charles of Service (1800 080 316) or Grandle of Charles of Service (1800 080 316) or Grandle of Charles of Service (1800 080 316) or Grandle of Charles of Service (1800 080 316) or Grandle of Charles of Service (1800 080 316) or Grandle of Charles of Service (1800 080 316) or Grandle of Charles of Service (1800 080 316) or Grandle of Charles of Service (1800 080 316) or Grandle of Charles of Service (1800 080 316) or Grandle of Charles of Service (1800 080 316) or Grandle of Charles of Charles of Service (1800 080 316) or Grandle of Charles of Char	or email CHQ_Bereavement@health.qld.gov.a  Inform Sepsis Care Coordinator of sepsis within 15 minutes following the treatment	considered  u  psis related death events of hospitalisation
status after 40–60mL/kg of fluid  • Prepare adrenaline (epinephrine) infusion by dilutin chloride 0.9% or glucose 5%; commence infusion a infusion chart for equivalent mL/hr for child's weight  • Call PICU, ICU or RSQ 1300 799 127  BEREAVEMENT  Refer to CHQ Bereavement Service (1800 080 316) or Grammer of	or email CHQ_Bereavement@health.qld.gov.a  Inform Sepsis Care Coordinator of sepsis within 15 minutes following the treatment  Altered AVPU	considered  nu  posis related death events of hospitalisation  t bundle?
status after 40–60mL/kg of fluid  • Prepare adrenaline (epinephrine) infusion by dilutin chloride 0.9% or glucose 5%; commence infusion a infusion chart for equivalent mL/hr for child's weight  • Call PICU, ICU or RSQ 1300 799 127  BEREAVEMENT  Refer to CHQ Bereavement Service (1800 080 316) or Grammer of	or email CHQ_Bereavement@health.qld.gov.a  □ Inform Sepsis Care Coordinator of sepsis within 15 minutes following the treatment □ Altered AVPU □ Poor skin perfusion; capillary refill ≥3 second	considered  nu  posis related death events of hospitalisation  t bundle?
status after 40–60mL/kg of fluid  • Prepare adrenaline (epinephrine) infusion by dilutin chloride 0.9% or glucose 5%; commence infusion a infusion chart for equivalent mL/hr for child's weight  • Call PICU, ICU or RSQ 1300 799 127  BEREAVEMENT  Refer to CHQ Bereavement Service (1800 080 316) or Grammer of	or email CHQ_Bereavement@health.qld.gov.a  Inform Sepsis Care Coordinator of sepsis within 15 minutes following the treatment  Altered AVPU	considered  nu  posis related death events of hospitalisation  t bundle?
status after 40–60mL/kg of fluid  • Prepare adrenaline (epinephrine) infusion by dilutin chloride 0.9% or glucose 5%; commence infusion a infusion chart for equivalent mL/hr for child's weight  • Call PICU, ICU or RSQ 1300 799 127  BEREAVEMENT  Refer to CHQ Bereavement Service (1800 080 316) or Grammer of	or email CHQ_Bereavement@health.qld.gov.a  ☐ Inform Sepsis Care Coordinator of sepsis within 15 minutes following the treatment ☐ Altered AVPU ☐ Poor skin perfusion; capillary refill ≥3 second country in the country is second content.	considered  nu  posis related death events of hospitalisation  t bundle?
status after 40–60mL/kg of fluid  • Prepare adrenaline (epinephrine) infusion by dilutin chloride 0.9% or glucose 5%; commence infusion a infusion chart for equivalent mL/hr for child's weight  • Call PICU, ICU or RSQ 1300 799 127  BEREAVEMENT  Refer to CHQ Bereavement Service (1800 080 316) or Grammer of	or email CHQ_Bereavement@health.qld.gov.a  □ Inform Sepsis Care Coordinator of sepsis within 15 minutes following the treatment □ Altered AVPU □ Poor skin perfusion; capillary refill ≥3 section □ Urine output less than 1mL/kg/hr	considered  nu  posis related death events of hospitalisation  t bundle?
status after 40–60mL/kg of fluid  • Prepare adrenaline (epinephrine) infusion by dilutin chloride 0.9% or glucose 5%; commence infusion a infusion chart for equivalent mL/hr for child's weight  • Call PICU, ICU or RSQ 1300 799 127  BEREAVEMENT  Refer to CHQ Bereavement Service (1800 080 316) or Grammer of	or email CHQ_Bereavement@health.qld.gov.a  □ Inform Sepsis Care Coordinator of sepsis within 15 minutes following the treatment □ Altered AVPU □ Poor skin perfusion; capillary refill ≥3 second up to the country of t	considered  nu  posis related death events of hospitalisation  t bundle?
status after 40–60mL/kg of fluid  • Prepare adrenaline (epinephrine) infusion by dilutin chloride 0.9% or glucose 5%; commence infusion a infusion chart for equivalent mL/hr for child's weight  • Call PICU, ICU or RSQ 1300 799 127  BEREAVEMENT  Refer to CHQ Bereavement Service (1800 080 316) or Grammer of	or email CHQ_Bereavement@health.qld.gov.a  □ Inform Sepsis Care Coordinator of sepsis within 15 minutes following the treatment □ Altered AVPU □ Poor skin perfusion; capillary refill ≥3 second upon the second policy □ Resolving signs of sepsis • De-escalate as per local policy	considered  au  posis related death events of hospitalisation  a bundle?  conds or cold extremities
status after 40–60mL/kg of fluid  • Prepare adrenaline (epinephrine) infusion by dilutin chloride 0.9% or glucose 5%; commence infusion a infusion chart for equivalent mL/hr for child's weight  • Call PICU, ICU or RSQ 1300 799 127  BEREAVEMENT  Refer to CHQ Bereavement Service (1800 080 316) or Grammer of	or email CHQ_Bereavement@health.qld.gov.a  □ Inform Sepsis Care Coordinator of sepsis within 15 minutes following the treatment □ Altered AVPU □ Poor skin perfusion; capillary refill ≥3 second up to the country of t	considered  au  Disis related death events of hospitalisation  a bundle?  Considered





	(Affix identification	label here	e)		
URN:					
Family name:					
Given name(s):					
Address:					
Date of birth:		Sex:	М	F	

#### **Sepsis Management Plan**

**DETERIORATING OR PERSISTENT SIGNS OF SEPSIS** Level of care: Critical

**RESOLVING SIGNS OF SEPSIS** Level of care: Inpatient

#### COMMUNICATE

#### Discussions with family to include:

- Explanation of sepsis
- Parent and carer information sheet (tear off Information for Parents page at back)
- Family questions
- · Goals of care
- Social work, welfare support and other allied health services
- Indigenous Health Liaison Officers (IHLO)
- Interpreter supports

#### Discussions with family to include:

- Explanation of sepsis
- Parent and carer information sheet (tear off Information for Parents page at back)
- Family questions
- · Social work and welfare support
- Indigenous Health Liaison Officers (IHLO)
- Interpreter supports

#### **MONITOR**

#### Continuous: • SpO<sub>2</sub>

- Heart rate
- Arterial blood pressure (if required) Respiratory rate

#### 15 minutes:

- AVPU
- · Non-invasive blood pressure
- · Capillary refill time

#### 60 minutes:

- Strict fluid balance
- Temperature (until resolved) Urine output
- 4 hourly:
- Lactate
- Blood sugar level
- Venous blood gas Temperature (once resolved)

#### Continuous:

- · SpO<sub>2</sub>
- Respiratory rate

#### 60 minutes:

- Blood pressure
- Strict fluid balance
- Temperature (until resolved) Urine output

Heart rate

- 4 hourly:
- AVPU
- Temperature (once resolved)

#### **REASSESS**

Patients may move between streams according to clinical response. Patients who are deteriorating or have persistent signs of sepsis require more frequent monitoring. Obtain senior medical officer advice on changing sepsis management plan stream.

#### Clinically reassess after interventions, monitored vital sign changes or every 60 minutes as a minimum:

- Tachypnoea (CEWT respiratory score ≥2)
- Tachycardia (CEWT heart rate score ≥2)
- Hypotension (CEWT blood pressure score ≥2)
- Altered AVPU
- Poor skin perfusion; capillary refill ≥3 seconds or cold extremities
- Urine output less than 1mL/kg/hr
- Lactate ≥2mmol/L (4 hourly)

If deteriorating or persistent signs of sepsis are still present:

- Escalate via local policy
- · Notify Senior Medical Officer and call PICU, ICU or RSQ 1300 799 127

#### Clinically reassess after interventions, monitored vital sign changes or every 60 minutes as a minimum:

- Tachypnoea (CEWT respiratory score ≤1)
- Tachycardia (CEWT heart rate score ≤1)
- Hypotension (CEWT blood pressure score ≤1)
- Improving AVPU
- Improved skin perfusion; capillary refill <3 seconds or warm extremities
- Urine output greater than or equal to 1mL/kg/hr

After 12 hours, if no intervention reassess every 4 hours

After 24 hours, if no intervention follow local de-escalation policy

#### **INVESTIGATE**

### Collect relevant outstanding microbiology samples:

- Urine Blood cultures
- ☐ CSF (when stable) Other relevant sources
- ☐ Stool (e.g. surgical specimens following
- source control) Respiratory

#### Collect relevant outstanding microbiology samples:

- Urine Blood cultures
- ☐ CSF Other relevant sources
- (e.g. surgical specimens following Stool
- source control) Respiratory

#### CONTINUE to next page





(Affix identification lab	el here	)		
URN:				
Family name:				
Given name(s):				
Address:				
Date of birth:	Sex:	M	F	

#### Sepsis Management Plan (continued)

DETERIORATING OR PERSISTENT SIGNS OF SEPSIS

Level of care: Critical

RESOLVING SIGNS OF SEPSIS Level of care: Inpatient

#### ANTIMICROBIAL OPTIMISATION

- · Reconsider source and need for source control
- Review microbiology results in consultation with laboratory
- Review appropriateness of antimicrobial cover and consider additional risk factors
- Consider ID expert guidance as per local referral pathway.
   QCH oncall service available Ph: 07 3068 1111
- Ensure Therapeutic Drug Monitoring where appropriate
- Review microbiology results in consultation with laboratory
- Review appropriateness of antimicrobials and consider de-escalation, targeting or cessation

#### **DOCUMENT**

#### **Antimicrobial Stewardship:**

- Document confirmed or suspected source of infection in health record
- Document plan to continue, change or cease antimicrobials
- Consider longer-term central IV access if required
- Review antimicrobial allergy history if applicable and refer to ID or immunology for assessment

#### Other documentation:

- Document sepsis in health record
- Document when patient is seen by Sepsis Care Coordinator
- Document variations to assist future optimisation of the pathway

#### **Antimicrobial Stewardship:**

- Document confirmed or suspected source of infection in health record
- Document plan to continue, change or cease antimicrobials
- Review antimicrobial allergy history if applicable and refer to ID or immunology for assessment

#### Other documentation:

- Document sepsis in health record
- Document when patient is seen by Sepsis Care Coordinator
- Document variations to assist future optimisation of the pathway

#### HANDOVER AND DISCHARGE

#### Handover to ward:

- □ Document psychosocial support required in health record (e.g. social work, IHLO, interpreter)
- Document clinicians involved in handovers in the health record
- Involve parents and carers in handover and provide information
- Handover to also include provisional sepsis diagnosis, comorbidities, management plan for medicines and medical conditions

#### Discharge planning:

- · Give resources to family
- · Identify GP and document in health record
- · Discuss supports required with family and GP
- Consider nurse navigator, hospital in the home or other referral
- · Give local patient experience survey to family

#### **RESOURCES**

#### Clinical:

- Queensland Paediatric Sepsis Program clinical resources for health professionals
- Children's Resuscitation Emergency Drug Dosage Guide (CREDD). Consider using CREDD for weight adjusted dosing measurements
- · National Sepsis Clinical Care Standard, including discharge planning guide, GP letter template and other resources
- Surviving Sepsis Campaign Guidelines January 2020

#### Family:

- · Queensland Paediatric Sepsis Program family resources
- Find an Aboriginal Community Controlled Health Organisation (ACCHO) near you

#### Bereavement:

· Children's Health Queensland Bereavement Service

# Table 1: PAEDIATRIC Empiric Prescribing Guidelines for Community Acquired Sepsis

• Where appropriate, screen patient for additional risk factors such as vaccination status, recent travel, multi-drug resistant organisms, immunocompromise, animal exposure, antenatal exposure or water-exposed soft tissue or skeletal infections. Contact paediatric ID specialist or microbiologist for advice

• Antimicrobial should be assessed with culture results and ID or microbiology at 24 to 48 hours of antimicrobial therapy

Pebrile   Pebr	Suspected s		ssed with culture results and ID or microbiology at <b>24 to 48</b> hours of antir	Immediate severe type hypersensitivity
Non-recision please manage as per the Pleadints: Serptis Analysis of Pathway 'Uestwoy'  Septis shock requiring indotrops'  An Lauscuss ADD Celanianon' TEU'S Wincomycin to preprintal agring where not already a commended in Analysis of the Pleadints' Service Please and Please			Initial, empirical antibiotic regimen	(e.g. anaphylaxis) to first line antimicrobial)**
septic shock requiring incorporate and already recommended of the factors for meliodiosis (wet season or flooting) REPLAR Coldination with Meloopsiers and or flooting) REPLAR Coldination with Meloopsiers and or flooting) REPLAR Coldination with Meloopsiers and flooting) REPLAR Coldination with Meloopsiers and Plant (Coldination) Replaced Coldination (Coldination) Replaced Replac		Normal Neutropenia		
Septis (bource unknown, but bacterial memority of conformation) PLUS Gentamion' IV PLUS (Conformation) PLU			where not already recommended  EXCEPT in North Queensland if risk factors for melioidosis (wet season or flooding) REPLACE Cefotaxime with Meropenem and	
possible OR Bacterial Meningitis  - ceriforAximE (or ceriforAxionE) IV PLUS Vencomyon IV Florence properties cocci in CSF - ceriforAximE (or ceriforAxionE) IV PLUS Vencomyon IV - ceriforAximE IV Vencomyon IV Vencomyon IV Vencomyon IV - ceriforAximE IV Vencomyon			cefOTAXIME IV PLUS Ampicillin (OR Amoxicillin) IV	• cefOTAXIME IV
Sepsis (source   Functional Sepsis   Sepsis   Sepsis (source   Functional Sepsis   Sep	possible <i>OR</i> Bacterial	8	cefOTAXIME (OR cefTRIAXONE) IV  If Gram positive cocci in CSF	
**Sepsis (source unknown)** unk bacterial meningitis excluded;  **Batcerial pneumonial (Community) in PLUS Genteminol* IV  **Batcerial pneumonial (Community) in PLUS Genteminol* IV PLUS Gent	Mennigius		All ages – if encephalitis suspected: ADD Aciclovir IV	• ciPROFLOXAcin IV PLUS Vancomycin IV
Sepais (source unknown, but bacterial meningitist excluded)   Sepais (source unknown, but bacterial meningitist)   Sepais (source unknown, but bacterial meningitist)   Sepais (source unknown, but bacterial meningitist)   Sepais (source unknown)			Ampicillin (OR Amoxicillin) IV PLUS Gentamicin* IV  If at risk of nmMRSA	
If at risk of mMIRSA   certoTAXIME (OR certTRIAXONE) IV PLUS IncOMYCIN   ciPROFLOXAGIN IV PLUS Lincomycin (OR Clindamycin) IV If at risk of millit-resistant MRSA   certoTAXIME (OR certTRIAXONE) IV PLUS Vancomycin IV   ciPROFLOXAGIN IV PLUS Vancomycin IV   ciPROFLOXAGIN IV PLUS Vancomycin IV   viproflamycin IV   ciPROFLOXAGIN IV PLUS Vancomycin IV   viproflamycin IV   vi	unknown,		(OR Clindamycin) IV Infants and children older than 2 months of age	
GPC Clindamycin]   V	meningitis		If at risk of nmMRSA	
Neonates and inflants up to 2 months of age			(OR Clindamycin) IV  If at risk of multi-resistant MRSA	
Ampicillin (OR Amoxicillin) IV PLUS Gentamion' IV   - cefOTAXIME IV   Infants and children more than 2 months of age   - cefOTAXIME (OR cefTRIAXONE) IV   Sewere pneumonia (requiring PICU admission)   - all ages: cefOTAXIME (OR cefTRIAXONE) IV   Empyema OR S. aureus (including nmMRSA) pneumonia suspected   - cefOTAXIME (OR cefTRIAXONE) IV PLUS lincOMYCIN (OR Clindamycin) IV   If life threatening pneumonia/empyema OR multi-resistant MRSA suspected   - cefOTAXIME (OR cefTRIAXONE) IV PLUS lincOMYCIN (OR Clindamycin) IV   If life threatening pneumonia/empyema OR multi-resistant MRSA suspected   - cefOTAXIME (OR cefTRIAXONE) IV PLUS lincOMYCIN (OR Clindamycin) IV   OR Clindamycin) IV   If life threatening pneumonia/empyema OR multi-resistant MRSA suspected   - cefOTAXIME (OR cefTRIAXONE) IV PLUS Gentamicin' IV PLUS   - cefOTAXIME (OR cefTRIAXONE) IV PLUS Metronidazole IV   Metronidazole IV   - Ampicillin (OR Amoxicillin) IV PLUS Gentamicin' IV PLUS   - cefOTAXIME (OR cefTRIAXONE) IV PLUS Metronidazole IV   - cefOTAXIME (OR Amoxicillin) IV PLUS Gentamicin' IV   - centamicin' IV   - ce				CIPROFLOXACIN IV PLUS Vancomycin IV
Infants and children more than 2 months of age				cefOTAXIME IV
Severe pneumonia (requiring PICU admission)   - All ages: cel'OTAXIME   V				
Penemonia (Community acquired)  - All ages: cefOTAXIME IV.  - If empyema OR saurues (including nmMRSA) pneumonia suspected - cefOTAXIME (OR cefTRAXONE) IV PLUS lincOMYCIN - (OR Clindamycin) IV.  - If life threatening pneumonia/empyema OR multi-resistant MRSA suspected - cefOTAXIME (OR cefTRAXONE) IV PLUS lincOMYCIN - (OR Clindamycin) IV.  - CefOTAXIME (OR cefTRAXONE) IV PLUS lincOMYCIN - (OR Clindamycin) IV PLUS Gentamicin* IV PLUS - Ampicillin (OR Amoxicillin) IV PLUS Gentamicin* IV PLUS - Ampicillin (OR Amoxicillin) IV PLUS Gentamicin* IV PLUS - Ampicillin (OR Amoxicillin) IV PLUS Gentamicin* IV - CefOTAXIME (OR cefTRAXONE) IV PLUS Metronidazole IV - IncoMYCIN (OR Clindamycin) IV PLUS Gentamicin* IV - Central (Progress of age and NOT Hib immune, with skeletal infection, periorbital cellulitis with a skin source OR severe cellulitis - Fluclosacillin IV - Fluc			Benzylpenicillin IV	cefOTAXIME (OR cefTRIAXONE) IV
Community acquired   Filempyema OR S. aureus (including mmMRSA) pneumonia suspected   celfOTAXIME   OR CefTRIAXONE)   V PLUS linCOMYCIN   ciPROFLOXAcin   V PLUS Lincomycin   OR Clindamycin)   V   If life threatening pneumonialempyema OR multi-resistant MRSA suspected   celfOTAXIME   OR CefTRIAXONE)   V PLUS linCOMYCIN   (OR Clindamycin)   V PLUS linCOMYCIN   (OR Clindamycin)   V PLUS Vancomycin   V   Central   Commonstration				
acquired)  - cefOTAXIME (OR cefTRIAXONE) IV PLUS linCOMYCIN (OR Clindamycin) IV  - cefOTAXIME (OR cefTRIAXONE) IV PLUS linCOMYCIN (OR Clindamycin) IV  - cefOTAXIME (OR cefTRIAXONE) IV PLUS linCOMYCIN (OR Clindamycin) IV PLUS vancomycin IV  - cefOTAXIME (OR cefTRIAXONE) IV PLUS linCOMYCIN (OR Clindamycin) IV PLUS vancomycin IV  - cefOTAXIME (OR cefTRIAXONE) IV PLUS linCOMYCIN (OR Clindamycin) IV PLUS vancomycin IV  - cefOTAXIME (OR cefTRIAXONE) IV PLUS dentamicin* IV PLUS  - cefOTAXIME (OR cefTRIAXONE) IV PLUS dentamicin* IV PLUS  - cefOTAXIME (OR cefTRIAXONE) IV PLUS dentamicin* IV  - cefOTAXIME IV PLUS dentamicin* IV plus dentam		THE STATE OF THE S		ciPROFLOXAcin IV PLUS Vancomycin IV
CefOTAXIME (OR cefTRIAXONE) IV PLUS linCOMYCIN (OR Clindamycin) IV PLUS Vancomycin IV			cefOTAXIME (OR cefTRIAXONE) IV PLUS linCOMYCIN     (OR Clindamycin) IV	
Intra-abdominal source				
Metronidazole IV  Innary source  All ages and Hib immune, with skeletal infection, periorbital cellulitis with a skin source OR severe cellulitis  Flucloxacillin IV  All ages and Hib immune, with skeletal infection, periorbital cellulitis with a skin source OR severe cellulitis  Flucloxacillin IV  Flucloxacillin IV  Flucloxacillin IV  If younger than 5 years of age and NOT Hib immune, with skeletal infection, periorbital cellulitis OR orbital cellulitis (all ages)  - cefOTAXIME IV  If at risk of mmMRSA  - ADD lincOMYCIN (OR Clindamycin) IV to appropriate therapy as above  If at risk of multi-resistant MRSA  - ADD Vancomycin IV to appropriate therapy as above  Suspected necrotising fasciitis  - cefOTAXIME IV PLUS Vancomycin IV PLUS lincOMYCIN (OR Clindamycin) IV PLUS lincOMYCIN (OR Clindamycin) IV PLUS consider IVIG 2g/kg  If external wound/inoculation associated with necrotising fasciitis  - Meropenem IV PLUS Vancomycin IV PLUS lincOMYCIN (OR Clindamycin) IV  Open fractures with severe tissue damage and contamination  - Piperacillin/Tazobactam IV  Consider removal of device  - Piperacillin/Tazobactam IV PLUS Vancomycin IV PLUS Vancomycin IV  - cefTAZIDIME IV PLUS Vancomycin IV  - cefTAZIDIME IV PLUS Vancomycin IV  - vancomycin IV PLUS Lincomycin (OR Clindamycin) IV  - cefTAZIDIME IV PLUS Vancomycin IV  - vancomycin IV PLUS Lincomycin (OR Clindamycin) IV				
All ages and Hib immune, with skeletal infection, periorbital cellulitis with a skin source OR severe cellulitis   Flucloxaciillin IV   - linCOMYCIN (OR Clindamycin) IV				cefOTAXIME (OR cefTRIAXONE) IV PLUS Metronidazole IV
Severe cellulitis or skeletal or soft tissue infection  If a risk of multi-resistant MRSA  - ADD linCOMYCIN (OR Clindamycin) IV to appropriate therapy as above  Suspected necrotising fasciitis  - cefoTAXIME IV   If a risk of multi-resistant MRSA  - ADD Vancomycin IV to appropriate therapy as above  - ciPROFLOXAcin IV PLUS linCOMYCIN (OR Clindamycin) IV to appropriate therapy as above  - ciPROFLOXAcin IV PLUS linCOMYCIN (OR Clindamycin) IV If a risk of multi-resistant MRSA  - ADD Vancomycin IV to appropriate therapy as above  - ciPROFLOXAcin IV PLUS Vancomycin IV PLUS Vancomycin IV PLUS linCOMYCIN (OR Clindamycin) IV PLUS Vancomycin IV PLUS linCOMYCIN (OR Clindamycin) IV PLUS Vancomycin IV PLUS linCOMYCIN (OR Clindamycin) IV PLUS Vancomycin IV Vancomycin IV PLUS Vancomycin IV Van	Urinary source	6 9	Ampicillin (OR Amoxicillin) IV PLUS Gentamicin* IV	Gentamicin* IV
If younger than 5 years of age and NOT Hib immune, with skeletal infection, periorbital cellulitis OR orbital cellulitis (all ages)   cefOTAXIME IV				
* cefOTAXIME IV				, , ,
Severe cellulitis or skeletal or soft tissue infection  If at risk of nmMRSA  - ADD linCOMYCIN (OR Clindamycin) IV to appropriate therapy as above   • ciPROFLOXAcin IV PLUS linCOMYCIN (OR Clindamycin) IV fat risk of multi-resistant MRSA  - ADD Vancomycin IV to appropriate therapy as above   • ciPROFLOXAcin IV PLUS Vancomycin IV Suspected necrotising fasciitis  - cefoTAXIME IV PLUS Vancomycin IV PLUS linCOMYCIN (OR Clindamycin) IV PLUS linCOMYCIN (OR Clindamycin) IV PLUS consider IVIG 2g/kg	· ·		, , , , , , , , , , , , , , , , , , , ,	7.1
Severe cellulitis or skeletal or soft tissue infection  **ADD linCOMYCIN** (OR Clindamycin) IV to appropriate therapy as above  **IROFLOXAcin** IV PLUS linCOMYCIN** (OR Clindamycin) IV  **If at risk of multi-resistant MRSA*  **ADD Vancomycin** IV to appropriate therapy as above  **Suspected necrotising fasciitis*  **CefOTAXIME** IV PLUS Vancomycin** IV PLUS linCOMYCIN** (OR Clindamycin) IV PLUS Vancomycin** IV PLUS linCOMYCIN** (OR Clindamycin) IV  **Open fractures with severe tissue damage and contamination**  **Piperacillin/Tazobactam** IV PLUS Vancomycin** IV PL				CIPROFLOXACIN IV PLUS IInCOMYCIN (OR Clindamycin) IV
or skeletal or soft tissue infection  • ADD Vancomycin IV to appropriate therapy as above  • ciPROFLOXAcin IV PLUS Vancomycin IV Suspected necrotising fasciitis  • cefOTAXIME IV PLUS Vancomycin IV PLUS linCOMYCIN (OR Clindamycin) IV PLUS consider IVIG 2g/kg  • Meropenem IV PLUS Vancomycin IV PLUS linCOMYCIN (OR Clindamycin) IV PLUS linCOMYCIN (OR Clindamycin) IV PLUS Vancomycin IV PLUS linCOMYCIN (OR Clindamycin) IV Open fractures with severe tissue damage and contamination  • Piperacillin/Tazobactam IV  Central venous access device source  • Piperacillin/Tazobactam IV PLUS Vancomycin IV Vancomycin IV PLUS Vancomycin IV Vancomycin IV PLUS Vancomycin IV Vancomyci	0	.,,,	ADD linCOMYCIN (OR Clindamycin) IV to appropriate therapy as above	• ciPROFLOXAcin IV PLUS linCOMYCIN (OR Clindamycin) IV
* cefOTAXIME IV PLUS Vancomycin IV PLUS linCOMYCIN (OR Clindamycin) IV PLUS linCOMYCIN (OR Clindamycin) IV PLUS consider IVIG 2g/kg  If external wound/inoculation associated with necrotising fasciitis  * Meropenem IV PLUS Vancomycin IV PLUS linCOMYCIN (OR Clindamycin) IV  Open fractures with severe tissue damage and contamination  * Piperacillin/Tazobactam IV  Central venous access device source  Toxic shock syndrome  * cefAZolin IV PLUS Lincomycin (OR Clindamycin) IV PLUS Vancomycin IV  * cefTAZIDIME IV PLUS Vancomycin IV PLUS Lincomycin (OR Clindamycin) IV PLUS Vancomycin IV PLUS Vancomycin IV PLUS Lincomycin (OR Clindamycin) IV	or skeletal or		ADD Vancomycin IV to appropriate therapy as above	ciPROFLOXAcin IV PLUS Vancomycin IV
* Meropenem IV PLUS Vancomycin IV PLUS linCOMYCIN (OR Clindamycin) IV      *Open fractures with severe tissue damage and contamination     *Piperacillin/Tazobactam IV      *Central venous access device source      *Toxic shock syndrome  *Open fractures with severe tissue damage and contamination  *Piperacillin/Tazobactam IV  *Open fractures with severe tissue damage and contamination  *Piperacillin/Tazobactam IV  *Open fractures with severe tissue damage and contamination  *Piperacillin/Tazobactam IV  *Open fractures with severe tissue damage and contamination  *Piperacillin/Tazobactam IV  *Open fractures with severe tissue damage and contamination  *Piperacillin/Tazobactam IV  *Open fractures with severe tissue damage and contamination  *CiPROFLOXAcin IV PLUS linCOMYCIN (OR Clindamycin) IV  *Open fractures with severe tissue damage and contamination  *Piperacillin/Tazobactam IV  *Plus Vancomycin IV  *PLUS Vancomycin IV  *Vancomycin IV  *PLUS Lincomycin (OR Clindamycin) IV  *PROFLOXAcin IV PLUS Vancomycin IV  *PLUS Lincomycin IV  *PLUS Lincomycin IV  *PLUS Lincomycin (OR Clindamycin) IV  *PLUS Lincomycin IV  *PLUS Linco	infection		cefOTAXIME IV PLUS Vancomycin IV PLUS linCOMYCIN     (OR Clindamycin) IV PLUS consider IVIG 2g/kg	
Central venous access device source  Toxic shock syndrome  Piperacillin/Tazobactam IV  Consider removal of device Piperacillin/Tazobactam IV PLUS Vancomycin IV  Consider removal of device Piperacillin/Tazobactam IV PLUS Vancomycin IV  Consider removal of device Piperacillin/Tazobactam IV PLUS Vancomycin IV  Consider removal of device  C			Meropenem IV PLUS Vancomycin IV PLUS linCOMYCIN     (OR Clindamycin) IV	
Central venous access device source  Toxic shock syndrome  Consider removal of device  Piperacillin/Tazobactam IV PLUS Vancomycin IV  • cefTAZIDIME IV PLUS Vancomycin IV  • cefTAZIDIME IV PLUS Vancomycin IV  Vancomycin IV PLUS Lincomycin (OR Clindamycin) IV PLUS Vancomycin PLUS consider IVIG 2g/kg				ciPROFLOXAcin IV PLUS linCOMYCIN (OR Clindamycin) IV
device source       • Piperacillin/Tazobactam IV PLUS Vancomycin IV       • cefTAZIDIME IV PLUS Vancomycin IV         Toxic shock syndrome       • ceFAZolin IV PLUS Lincomycin (OR Clindamycin) IV PLUS Vancomycin PLUS consider IVIG 2g/kg       • Vancomycin IV PLUS Lincomycin (OR Clindamycin) IV	Central	Sometimes of	·	
Toxic shock syndrome   • ceFAZolin IV PLUS Lincomycin (OR Clindamycin) IV PLUS Vancomycin PLUS Consider IVIG 2g/kg • Vancomycin IV PLUS Lincomycin (OR Clindamycin) IV			Piperacillin/Tazobactam IV PLUS Vancomycin IV	cefTAZIDIME IV PLUS Vancomycin IV
	Toxic shock s		PLUS consider IVIG 2g/kg	Vancomycin IV PLUS Lincomycin (OR Clindamycin) IV

<sup>\*</sup> If Pseudomonas aeruginosa is cultured, seek ID advice on appropriate directed therapy.

<sup>\*\*</sup> The recommendations provided for immediate type hypersensitivity in this table are for an initial dose only in the emergency treatment of sepsis. Please contact a paediatric ID specialist for any subsequent dosing.

For more information, and **ongoing** prescribing information please refer to <u>'CHQ Paediatric Antibiocard: Empirical Antibiotic Guidelines'</u> and the <u>'CHQ guideline: Empiric antibiotic guidelines for Paediatric Intensive care unit (PICU)'</u>.

Page 5 of 6

# Table 2: Antimicrobial Dose Recommendations for Sepsis by Age

- Term neonates >36 weeks post-menstrual age to adolescents.
- For premature neonates, refer to NeoMedQ, ANMF or Neofax; available via CKN or QCH Guidelines.

Antimicrobial	Dose recommend	dation by age (normal renal function)		
Aciclovir IV	Birth to 3 months of age	20mg/kg IV 8 hourly		
	Older than 3 months of age and less than 12 years of age	• 500mg/m² (maximum 1g) IV 8 hourly		
	12 years of age and older	• 10mg/kg (maximum 1g) IV 8 hourly		
Ampicillin (OR Amoxicillin) IV	Neonates	Week 1 of life: 50mg/kg IV 12 hourly Week 2–4 of life: 50mg/kg IV 8 hourly Meningitis: 100mg/kg/dose (on ID advice)		
	Older than 1 month of age	• 50mg/kg (maximum 2g) IV 6 hourly		
Benzylpenicillin IV	Neonates	Week 1 of life: 60mg/kg IV 12 hourly     Week 2–4 of life: 60mg/kg IV 8 hourly		
	Older than 1 month of age	60mg/kg (maximum 2.4g) IV 6 hourly		
cefaZOLin IV	Neonates	Seek ID/specialist advice		
	Older than 1 month of age	• 50mg/kg IV 8 hourly (maximum 2g)		
cefOTAXIME IV or IM* for neonate	Neonates	Week 1 of life: 50mg/kg IV/IM 8 hourly  Week 2–4 of life: 50mg/kg IV/IM 6 hourly		
	Older than 1 month of age	• 50mg/kg (maximum 2g) IV/IM 6 hourly		
cefTRIAXONE IV or IM*	Neonates	cefTRIAXONE contra-indicated (risk of kernicterus) – use cefOTAXIME		
	Older than 1 month of age	50mg/kg (maximum 2g) IV/IM 12 hourly		
cefTAZIDIME IV	Neonates	• 50mg/kg IV 12 hourly		
	Older than 1 month of age	• 50mg/kg (maximum 2g) IV 8 hourly		
ciPROFLOXAcin IV	Neonates	Seek ID/specialist advice		
	Older than 1 month of age	10mg/kg (maximum 400mg) IV 8 hourly		
Clindamycin IV	Neonates	• 7mg/kg IV 8 hourly		
	Older than 1 month of age	• 10mg/kg (maximum 600mg) IV 6 hourly		
Flucloxacillin IV	Neonates	Week 1 of life: 50mg/kg IV 12 hourly Week 2–3 of life: 50mg/kg IV 8 hourly Week 4 of life: 50mg/kg IV 6 hourly		
	Older than 1 month of age	• 50mg/kg (maximum 2g) IV 6 hourly		
Gentamicin IV	Neonates	Week 1–4 of life: 5mg/kg IV once daily		
	Older than 1 month and less than 10 years of age	• 7.5mg/kg IV once daily (maximum 320mg)		
	10 years of age and older	7mg/kg IV once daily (maximum 700mg)		
	ALL ages: perform Therapeutic Drug Monitoring (TDM) – d check trough pre-2nd dose)	ose based on Adjusted body weight (neonates or renal impairment,		
IinCOMYCIN IV	Neonates	No neonatal dosing recommendation for linCOMYCIN – use Clindamycin IV		
	Older than 1 month of age	• 15mg/kg (maximum 1.2g) IV 8 hourly		
Meropenem IV	All ages	40mg/kg (maximum 2g) IV 8 hourly		
Metronidazole IV	Neonates	15mg/kg IV load, then 7.5mg/kg IV 8 hourly		
	Older than 1 month of age	• 7.5mg/kg (maximum 500mg) IV 8 hourly		
Piperacillin/ Tazobactam IV	Neonates	Week 1 of life: 100mg/kg IV 12 hourly     Week 2–4 of life: 100mg/kg IV 8 hourly		
(dose based on piperacillin component)	Older than 1 month of age	• 100mg/kg (maximum 4g) IV 6 hourly		
Vancomycin IV	Neonates	Week 1 of life: 15mg/kg IV 12 hourly     Week 2–4 of life: 15mg/kg IV 8 hourly		
	Older than 1 month of age	15mg/kg (maximum 750mg) IV 6 hourly		
	ALL ages: perform TDM – dose based on Actual body weight			
*Prioritise IV/IO access and a		ation in sepsis may result in subtherapeutic doses due to reduced muscular perfusion.		

- 1. Antibiotic Therapeutic Guidelines (Oct 2021). Therapeutic Guidelines Committee, North Melbourne, Victoria. Available on CKN
- 2. AMH Children's Dosing Companion [Online]. Adelaide: Australian Medicines Handbook Pty Ltd; 2020. Last updated July 2022. Available on CKN.

  3. The Australasian Neonatal Medicines Formulary (ANMF) [Online]. Accessed 6 Oct 2022. Last updated 11/10/22. Available on CKN.

  4. Neofax 2022. Micromedex Healthcare solutions. Truven Health Analytics. US. Available on CKN.

  5. NeoMedQ Neonatal Medicines [Online]. Accessed 6 Oct 2022. Last updated Aug 2019. Available on CKN.

  6. BNF for Children 1/10/22. BMJ Group, London, UK. Available on CKN.

# Table 3: PAEDIATRIC Antimicrobial Administration Guidelines for Community Acquired Sepsis

- · Commence IV antibiotics as soon as possible after blood cultures have been taken. Do not delay antibiotic administration while awaiting blood test results.
- If multiple IV antimicrobial orders are prescribed, administer in order of shortest to longest infusion times to ensure completed as quickly as possible. For example:
- » Septic shock requiring inotropes: inject IV cefotaxime over 3–5 minutes, followed by IV gentamicin over 30 minutes, followed by IV vancomycin over 60 minutes.
- Ensure adequate saline flush between incompatible agents.
- Where possible use separate dedicated lines for resuscitation fluid and for medications. If not possible, pause either the antibiotic or the resuscitation fluid to administer. You may administer via Y-site, but not concurrent delivery.
- Use CREDD where this is the locally recommended resource.

Antimicrobial (tradename/ brand)	Strength (powder volume) [volume]	Reconstitution	Final concentration PIV = Peripheral IV CVL = Central	Intravenous (IV) administration	Compatible IV fluids	Additional information
Aciclovir (DBL) Intravenous	25mg/mL [10mL; 20mL]	Reconstitution not required	PIV: Dilute to 5mg/mL     CVL: 25mg/mL	Infuse over     60 minutes	<ul><li>Sodium Chloride 0.9%</li><li>Glucose 5%</li><li>Hartmann's</li><li>Plasma-Lyte via Y-site</li></ul>	<ul><li>Extravasation risk</li><li>Ensure adequate hydration</li></ul>
Amoxicillin (Fisamox, Ibiamox, Amoxil) Intravenous	1g (0.8mL)	Water for injection     Add 9.2mL to 1g vial     (100mg/mL)	PIV or CVL:  • Dilute to 50mg/mL or weaker	Infuse over 30 minutes	Sodium Chloride 0.9%     Glucose 5%, 10%     via Y-site     Hartmann's	<ul><li>Flush well between aminoglycosides</li><li>Rapid IV injection may cause seizures</li></ul>
AMPicillin (Austrapen, Auspen, Ibimicyn) Intravenous	500mg (0.3mL) 1g (0.7mL)	Water for injection     Add 4.7mL to     500mg vial     Add 9.3mL to 1g vial     (100mg/mL)	PIV or CVL:  • Undiluted; 100mg/mL  • Dilute to 30mg/mL for infusion	• 50mg/kg UP TO ≤500mg: Inject undiluted over 3–5 minutes • 100mg/kg <i>OR</i> >500mg: Infuse over 15–30 minutes	Sodium Chloride 0.9%     Glucose 5%, 10%     Ringer's via Y-site	Flush well between aminoglycosides     Rapid IV injection may cause seizures
Benzylpenicillin (BenPen) Intravenous	600mg (0.4mL) 1.2g (0.8mL) 3g (2mL)	<ul> <li>Water for injection</li> <li>Add 1.6mL to 600mg vial</li> <li>Add 3.2mL to 1.2g vial</li> <li>Add 8mL to 3g vial (300mg/mL)</li> </ul>	PIV: Dilute to 60mg/mL     CVL: Undiluted; 300mg/mL	Infuse over 30 minutes	Sodium Chloride 0.9%     Glucose 5%     Plasma-Lyte via Y-site	Flush well between aminoglycosides     Rapid IV injection may cause electrolyte imbalance and seizures
CefaZOLin (AFT, Hospira, Sandoz, Alphapharm) Intravenous	1g (0.5mL)	Water for injection     Add 9.5mL to 1g vial     (100mg/mL)	PIV or CVL:  • Undiluted; 100mg/mL  • Dilute to 20mg/mL  for infusion	<ul> <li>Inject undiluted over 3–5 minutes; OR</li> <li>Infuse over 10–60 minutes</li> </ul>	<ul><li>Sodium Chloride 0.9%</li><li>Glucose 5%, 10%</li><li>Hartmann's</li><li>Plasma-Lyte via Y-site</li></ul>	Flush well between aminoglycosides
cefOTAXIME (Sandoz, DBL) Intravenous OR Intramuscular	1g (0.4mL) 2g (1mL)	Water for injection IV: Add 4.6mL to 1g vial Add 9mL to 2g vial (200mg/mL)	PIV or CVL:  • Undiluted; 200mg/mL  • Dilute to 60mg/mL for infusion	<ul> <li>Inject undiluted over 3–5 minutes; <i>OR</i></li> <li>Infuse over 15–30 minutes</li> </ul>	Sodium Chloride 0.9%     Glucose 5% , 10%     Hartmann's	Flush well between aminoglycosides     More rapid injection may cause cardiac arrhythmias
·		IM: • Add 2.6mL to 1g vial • Add 5mL to 2g vial (330mg/mL)	IM: • Undiluted; 330mg/mL		C-01039 Medication administry of solutions to be Injected	
cefTAZIDIME (Sandoz, AFT) Intravenous	1g (0.9mL) 2g (1.8mL)	<ul> <li>Water for injection</li> <li>Add 5mL to 1g vial</li> <li>Add 10mL to 2g vial (170mg/mL)</li> </ul>	PIV or CVL: • Undiluted; 170mg/mL • Dilute to 40mg/mL for infusion	<ul> <li>Inject undiluted over 3–5 minutes; <i>OR</i></li> <li>Infuse over 15–30 minutes</li> </ul>	<ul><li>Sodium Chloride 0.9%</li><li>Glucose: 5%, 10%</li><li>Hartmann's</li><li>Plasma-Lyte via Y-site</li></ul>	Flush well between aminoglycosides
CefTRIAXone (AFT, Alphapharm, Hospira) Intravenous OR	1g (0.6mL)	Water for injection IV: Add 9.4mL to 1g vial (100mg/mL)	PIV or CVL: • Dilute to 40mg/mL	Dilute and inject over 5 minutes; <i>OR</i> Infuse over 30 minutes	Sodium Chloride 0.9%     Glucose 5%, 10%     Incompatible with     Hartmann's & Ringer's	Flush well between aminoglycosides, or calcium containing solutions     Not recommended for use in neonates
Intramuscular		IM: • Add 2.3mL to 1g vial (350mg/mL)	IM: • Undiluted; 350mg/mL		C-01039 Medication administry of solutions to be Injected	

## Table 3 (continued)

Antimicrobial (tradename/ brand)	Strength (powder volume) [volume]	Reconstitution	Final concentration PIV = Peripheral IV CVL = Central	Intravenous (IV) administration	Compatible IV fluids	Additional information
Ciprofloxacin (Aspen, DBL) Intravenous	2mg/mL [100 <i>mL</i> ]	Reconstitution not required	PIV or CVL:  • Undiluted; 2mg/mL  • Dilute to 1mg/mL	Infuse over     60 minutes	<ul><li>Sodium Chloride 0.9%</li><li>Glucose: 5%, 10%</li><li>Hartmann's</li><li>Plasma-Lyte via Y-site</li></ul>	Extravasation risk     Ensure adequate hydration
Clindamycin (Mylan, Dalacin C) Intravenous	150mg/mL [4mL]	Reconstitution not required	PIV or CVL:  • Dilute to 18mg/mL or weaker	Infuse over     20–60 minutes     Maximum infusion     rate: 20mg/kg/hr or     30mg/minute	<ul><li>Sodium Chloride 0.9%</li><li>Glucose: 5%, 10%</li><li>Hartmann's</li><li>Plasma-Lyte via Y-site</li></ul>	Rapid IV injection may cause hypotension and cardiac arrest
Flucioxacillin (Flucil, Flubiciox, Hospira) Intravenous	500mg (0.4mL) 1g (0.7mL)	Water for injection     Add 9.6mL to 500mg vial     Add 19.3mL to 1g vial (50mg/mL)	PIV or CVL:  • Undiluted; 50mg/mL or dilute to convenient volume	Infuse over at least 30 minutes     May give over 3–5 minutes (phlebitis risk)	<ul><li>Sodium Chloride 0.9%</li><li>Glucose 5%</li><li>Hartmann's</li><li>Plasma-Lyte via Y-site</li></ul>	Extravasation risk     Flush well between aminoglycosides
Gentamicin (Pfizer) Intravenous	40mg/mL [2mL]	Reconstitution not required	PIV or CVL:  • Dilute to 10mg/mL or weaker	• Infuse over 30 minutes	<ul> <li>Sodium Chloride 0.9%</li> <li>Glucose: 5%, 10%</li> <li>Hartmann's</li> <li>Plasma-Lyte via Y-site</li> </ul>	Therapeutic drug monitoring (TDM) required Rapid IV injection may cause ototoxicity Flush well between cephalosporins and penicillin
Lincomycin (Lincocin, SXP) Intravenous	300mg/mL [2mL]	Reconstitution not required	PIV or CVL:  • Dilute to 10mg/mL or weaker	≤1g: Infuse over 60 minutes      >1g: Maximum infusion rate 1g/hour	<ul><li>Sodium Chloride 0.9%</li><li>Glucose 5%, 10%</li><li>Hartmann's</li><li>Plasma-Lyte via Y-site</li></ul>	Rapid IV injection may cause hypotension and cardiac arrest
Meropenem (DBL, Kabi, Ranbaxy) Intravenous	500mg (0.4mL) 1g (0.9mL)	<ul> <li>Water for injection</li> <li>Add 9.6mL to 500mg vial</li> <li>Add 19.1mL to 1g vial (50mg/mL)</li> </ul>	PIV or CVL:  • Undiluted; 50mg/mL or dilute to convenient volume	• Inject undiluted over 3–5 minutes; <i>OR</i> • Infuse over 15–30 minutes	<ul><li>Sodium Chloride 0.9%</li><li>Glucose 5%, 10%</li><li>Plasma-Lyte via Y-site</li></ul>	
Metronidazole (DBL, Claris, Sandoz) Intravenous	5mg/mL [100mL]	Reconstitution not required	PIV or CVL:  • Undiluted; 5mg/mL or dilute to a convenient volume	Infuse over 20–30 minutes	<ul> <li>Sodium Chloride 0.9%</li> <li>Glucose 5%</li> <li>Hartmann's via Y-site</li> <li>Plasma-Lyte via Y-site</li> </ul>	
Piperacillin/ Tazobactam (DBL, AFT, Kabi, Tazocin EF) Intravenous	Piperacillin 4000mg Tazobactam 500mg; (3mL)	Water for injection     Add 17mL to     4/0.5g vial     (200mg/mL)	PIV or CVL:  • Dilute to 90mg/mL or weaker	Infuse over     30 minutes	Sodium Chloride 0.9%     Glucose 5%     Hartmann's via Y-site (AFT, Tazocin EF only)     Plasma-Lyte via Y-site	Flush well between aminoglycosides     Concentrations expressed as piperacillin component
Vancomycin (DBL, AN, Vancocin CP, Alphapharm) Intravenous	500mg; 1g (powder volume negligible)	<ul> <li>Water for injection</li> <li>Add 10mL to 500mg vial</li> <li>Add 20mL to 1g vial (50mg/mL)</li> </ul>	PIV: Dilute to 5mg/mL or weaker  CVL: Dilute to 10mg/mL or weaker	• Infuse over 60–120 minutes	<ul> <li>Sodium Chloride 0.9%</li> <li>Glucose 5%, 10%</li> <li>Hartmann's</li> <li>Plasma-Lyte via Y-site</li> </ul>	TDM required  Extravasation risk  If Red Man Syndrome occurs, slow infusion rate

References:

The Royal Children's Hospital Paediatric Injectable Guidelines, June 2020, Melbourne, Australia. Available on CKN.
 Burridge, N., Ed. (2022). The Australian Injectable Drugs Handbook 8th edition. Collingwood, The Society of Hospital Pharmacists of Australia. Available on CKN.



Information for parents, carers and families of children with sepsis

# What is sepsis?

Sepsis happens when the body has an extreme response to an infection and starts to injure its own tissues and organs. Sepsis can be triggered by any infection (viral, fungal, bacterial) but most commonly occurs with bacterial infections of the brain, lungs, bladder, kidneys, abdomen, skin and soft tissues.

## Care for your child in hospital

Your child's healthcare team team will provide urgent treatments including:

- Insertion of a cannula, collection of blood tests and administration of antibiotics.
- Give fluids and other medicines, via a cannula, to support your child's circulation.
- Monitor your child's response to treatment.
- · Consult with a sepsis expert.
- Arrange for transfer to the most appropriate place for your child's care which may be a general ward or Paediatric Intensive Care Unit (PICU).

There will be many people in your child's healthcare team, which may include doctors, nurses and a social worker. You are your child's key support and advocate; let your healthcare team know about your child's condition, their progress and any changes that concern you.

Your healthcare team should talk to you about:

- What a diagnosis of sepsis means for your child in the short, medium and long term.
- Plans for your child's treatment, who will provide this care and their response to treatment.
- What to expect during your child's recovery.
- How to inform the healthcare team if you are concerned your child is getting worse.
- Support you can receive in hospital.



## Ryan's Rule

You and your family will be informed about your child's treatment options and involved in decisions about their care. If you have concerns that your child's health condition is getting worse or not improving, discuss this initially with the healthcare team. You can also search 'Ryan's Rule' on the Children's Health Queensland website to learn about raising concerns.





# Support for your family in hospital

Dealing with a complex health issue like sepsis and a hospital admission can be stressful and challenging for all family members. Speak to your child's healthcare team about ways to access additional support which may include:

- Social workers who can provide help to adjust and manage your child's health condition and admission.
- Welfare workers who can provide practical support with accommodation, finances, travel, and social needs.

#### Children and medical procedures

It is common for children to struggle with some medical procedures. Reassure your child of your support. It helps children to know what is going to



happen, why the procedure needs to happen and who will be involved. For more ideas, scan this QR code and read our blog on supporting your child through a procedure.

#### **Cultural support**

Let your healthcare team know if you need:





A translator or interpreter.



#### Sepsis resources

Sepsis on the Children's Health Queensland website has information for families including:

- 'Journeying through Sepsis' video series to support you through each stage of your child's sepsis journey.
- Paediatric Sepsis Family Support Network
- Paediatric Sepsis Peer Mentor Program.

For more information visit Sepsis on the Children's Health Queensland website at www.childrens.health.qld.gov.au/sepsis or scan the QR code below.

# Questions you could ask your child's healthcare team

- What will my child's treatment be?
- Who will provide this treatment?
- How will my child be affected by sepsis and it's treatment?
- What complications of sepsis and the treatment should I be aware of?
- How did my child become unwell with sepsis?
- Who is my main contact person within the hospital for my child's care?
- What should I expect as my child recovers in hospital after the initial critical care for sepsis?
- How can I escalate my concerns if my child is getting worse?
- What supports are available to me, my child and my family in hospital?
- What should I expect with my child's recovery after discharge from hospital?
- What are the potential long-term impacts of my child's sepsis diagnosis?
- Is my child likely to come back to hospital?
- What are signs my child is getting unwell again, and when should we return to hospital or our GP?
- What supports are available to my child and our family following discharge from hospital?





Illnesses can change – trust your gut feeling. Even if your child has recently had sepsis, if you think they may have sepsis again come back to hospital and ask 'Could it be sepsis?'.

Visit www.childrens.health.qld.gov.au/sepsis



# Sepsis is a **medical emergency** and needs immediate treatment.

Sepsis happens when the body has an extreme response to an infection and starts to injure its own tissues and organs. Sepsis can damage many parts of the body and can result in death. The best chance of getting better from sepsis is to treat it quickly.

Knowing if your child has sepsis can be difficult because many of the symptoms in the beginning are the same as mild infections. The difference is that your child's symptoms don't improve or may worsen.

Sepsis is rare, but any child can develop sepsis and we all need to know what to look out for.

You know your child best, so **trust your gut feeling**. If your child is more unwell than ever before or this illness is different from other times – ask your doctor or nurse **"Could it be sepsis?"**.

Cold skin Working A lot of hard to pain or very breathe estless Go to hospital or call 000 now Seizure Floppy Blotchy, blue Drowsy or or pale skin confused

Rash that doesn't fade

when pressed

ny ONE of these symptoms may mean your


child is very unwell and could have sepsis:





# Paediatric Sepsis checklist

If you think your child is not getting better, or they are getting sicker, trust your gut feeling. Tick the boxes that apply to your child and ask your doctor or nurse "Could it be sepsis?".





Illnesses can change – trust your gut feeling. Even if your child has recently seen a doctor, if you think they may have sepsis, come back to hospital and ask "Could it be sepsis?".